AstraZeneca gets Verus's $1.3 billion US asthma suit dismissed
This article was originally published in Scrip
Executive Summary
A US federal judge has granted AstraZeneca's motion to dismiss all nine counts of a complaint filed by US firm Verus Pharmaceuticals, which alleged the UK firm breached its contractual obligations under three R&D agreements signed in 2007 relating to a prospective paediatric asthma treatment.